Table 1 Demographic, laboratory and clinical variables in NAFLD subjects and controls
Variable | NAFLD subjects (n = 80) | Controls (n = 83) | p |
|---|---|---|---|
Age (years) (mean ± SD) | 53.7 ± 12.9 | 51.7 ± 17.2 | 0.401 |
Weight (kg) (mean ± SD) | 78.9 ± 17.7 | 71.3 ± 13.4 | 0.002 |
BMI (kg/m2) (mean ± SD) | 28.7 ± 5.6 | 25.3 ± 3.8 | 0.005 |
SBP (mm/Hg) (mean ± SD) | 121.7 ± 13.7 | 122.7 ± 16.3 | 0.655 |
DBP (mm/Hg) (mean ± SD) | 72.7 ± 9.5 | 75.4 ± 12.7 | 0.127 |
Hypertension (n/%) | 28 (35.0) | 13 (15.7) | 0.006 |
Diabetes (n/%) | 31 (38.8) | 7 (8.4) | 0.005 |
Dyslipidaemia (n/%) | 15 (18.8) | 14 (16.9) | 0.839 |
Previous cardiovascular diseases | 3 (3.75) | 0 | 0.341 |
Previous cerebrovascular events | 0 | 0 | 0.417 |
RHI (mean ± SD) | 1.85 ± 0.5 | 2.20 ± 0.6 | 0.005 |
Aix (%) (mean ± SD) | 144.3 ± 27.2 | 131.4 ± 31.4 | 0.006 |
PWV (mt/s) (mean ± SD) | 10.46 ± 2.1 | 9.61 ± 2.30 | 0.015 |
MMSE (mean ± SD) | 26.9 ± 1.6 | 28.0 ± 1.4 | 0.005 |
Liver stiffness, kPa | 9.37 ± 7.7 | 4.5 ± 0.4 | 0.005 |
NASH patients (n/%) | 52 | ||
Histology (%) | 52 (65) | ||
Kleiner steatosis grade 0–3 (mean/SD) | |||
1 (n/%) | 36 (45) | ||
2 (n/%) | 22 (27.5) | ||
3 (n/%) | 22 (27.5) | ||
Lobular inflammation grade 0–3 (mean/SD) | |||
0 (n/%) | 2 (2.5) | ||
1 (n/%) | 45 (56.3) | ||
2 (n/%) | 31 (38.8) | ||
3 (n/%) | 2 (2.5) | ||
Hepatocellular ballooning 0–2 (mean/SD) | |||
0 (n/%) | 23 (28.7) | ||
1 (n/%) | 35 (43.8) | ||
2 (n/%) | 22 (27.5) | ||
Stage of fibrosis (0–4) (mean/SD) | |||
0 (n/%) | 18 (22.5) | ||
1 (n/%) | 25 (31.3) | ||
2 (n/%) | 14 (17.5) | ||
3 (n/%) | 17 (21.3) | ||
4 (n/%) | 6 (7.5) | ||